Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13835686 | 1.00 | BACE1 (0.38) | BACE1BACE2APPSYKACP1 | |
| SCHEMBL13859337 | 0.89 | APP (0.34) | BACE1BACE2APPSYKACP1 | |
| SCHEMBL13835606 | 0.86 | MAPK14 (0.42) | BACE1BACE2ACP1 | |
| SCHEMBL13835609 | 0.86 | MAPK14 (0.42) | BACE1BACE2ACP1 | |
| SCHEMBL13836273 | 0.84 | BACE1 (0.39) | BACE1BACE2ACP1LMNA | |
| SCHEMBL13836275 | 0.84 | BACE1 (0.39) | BACE1BACE2ACP1LMNA | |
| SCHEMBL13836374 | 0.84 | BACE1 (0.40) | BACE1BACE2ACP1 | |
| SCHEMBL13836380 | 0.84 | BACE1 (0.40) | BACE1BACE2ACP1 | |
| SCHEMBL13836389 | 0.83 | ACP1 (0.39) | BACE1BACE2APPACP1 | |
| SCHEMBL13836385 | 0.83 | ACP1 (0.39) | BACE1BACE2APPACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785436-B2 | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | BACE1 2/4885BACE2 1/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.